Movin’ on up is Aurora Cannabis (TSX:ACB) Executive Vice President Cam Battley, who the company announced on Monday received a promotion to Chief Corporate Officer. Mr. Battley, who has also held the role of Senior Vice President of Aurora will become the new face of the company, dealing with everyone from shareholders to the press. Among his many new duties will be to liaison with Aurora Cannabis’ Board of Directors as the company continues its plans for growth over the next few years.
Battley recently made headlines during the height of Aurora’s spat with CanniMed Therapeutics (TSXCMED), calling the rival cannabis firm’s deal with Newstrike Resources Ltd. (TSX-V:HIP) “bizarre.” In another press-worthy moment, Battley commented on the recent decision by Attorney General Jeff Sessions to rescind the Obama-era “Cole memo,” saying what is bad for America is good for Canada. Aside from his work with Aurora, Battley serves on a number of boards, including as a member of the trade association for Health Canada Licensed Producers known as Cannabis Canada.
"Cam's experience, judgment, energy, and passion for this business have been key drivers in Aurora's rapid emergence as a leader in the global cannabis industry," said Aurora CEO Terry Booth. "I am extremely proud of the quality, competence and consistent execution of our executive team, and am delighted that Cam will be playing a central role with Aurora as we accelerate our domestic and international expansion."
Aurora shares are up 6.61 percent as of Monday afternoon, trading at $14.00 per unit on higher than average volume trading.
MYM Hails An Uber
I was gonna clean my room until I got high… Signing the “Uber of Cannabis” is MYM Nutraceuticals Inc. (CSE:MYM), who announced on Friday a deal to acquire Budly Software Inc. Budly is the developer of technology that connects consumers with dispensary delivery drivers right from their phone. The app is available for all major systems, including Android, iOS, and yes, even Windows Phone should anyone still own one.
MYM made headlines recently, most notable for their Northern Rivers Project in Australia, which received research and manufacturing licenses from the Office of Drug Control. The company announced that their Australian venture, formerly called PUF Ventures Australia, would now be known as Solaris Nutraceuticals Pty Ltd. Meanwhile, the Budly deal sees MYM acquiring the non-U.S. rights to Budly’s software in exchange for 800,000 shares of stock.
"The Budly software is a game-changer for MYM because it brings us one step closer to becoming a fully integrated global cannabis company," commented MYM CEO Rob Gietl. "Budly's clean and simple interface allows orders to be easily placed by patients, right on their phone, and provides extensive back-end management and logistics control for licensed producers and dispensaries."
MYM is down .24 percent per share as of Monday afternoon, trading at $4.10 per share.
Special Session Continued
It's the funk doctor spock smokin buddha on a train… Not to be left out of the Sessions brouhaha is Novus Acquisition and Development, Corp. (OTCMKTS:NDEV), Medical Cannabis Payment Solutions (OTC:REFG), and CLS Holdings USA, Inc. (OTCQB:CLSH). All three companies put out their own releases on Monday addressing the Justice Department’s new policy, each with their own spin. CLS called the move “disappointing,” Medical Cannabis tried to focus more on the Rohrabacher-Farr Amendment, and Novus put their faith in Congress.
“This was a very serious action and we sought consultation with our legal advisors on how this may affect Novus’ business model. While we understand that the Cole Memo is not a federal law, we believe Congress will enforce budgetary restrictions overriding the Justice Department actions,” said Frank Labrozzi, Chairman and CEO of Novus. Meanwhile, Sean Hullinger, Chief Legal Officer of Medical Cannabis Payment Solutions remarked, “Our ability to conduct business is entirely dependent on the continuing reauthorization of the Rohrabacher-Farr Amendment.”
In perhaps the most positive response to the whole fiasco to date, CLS Holdings CEO Jeff Binder said, “In a country that is divided on so many issues, we are encouraged by the polling of all Americans, which shows a clear majority support responsible medicinal and recreational marijuana policies. People with diseases such as PTSD, cancer, depression, anxiety, and chronic pain, to name a few, are positively affected by the responsible use of cannabis as prescribed by their physician or caretaker.”
Always remember though, “good people don’t smoke marijuana.”
Let's roll another joint… Returning from the 90’s is Kathy Ireland whose subsidiary of Level Brands, Inc. (NYSE:LEVB) Health and Wellness announced a licensing agreement with Isodiol International Inc. (CSE:ISOL) (OTCQB:ISOLF) on Monday. Isodial will develop new products under Ireland’s brand in exchange for $2 million in company shares and $62,500 in cash. Level will also receive a 3 percent royalty on any products sold.
"We look forward to benefiting from Kathy Ireland's proven track record in product strategy and marketing," said Isodiol President Marcos Agramont.
Roll joints bigger than King Kong's fingers… Celebrating a grand opening is Cannabis Science, Inc. (OTCPINK:CBIS) who announced on Monday the news about its first two Pre ICO pharmacies in California. A Pharmacy Automation and Inventory Tracking System will be used to manage the pharmacies. Cannabis Science hopes to expand into New York City and Washington D.C. shortly.
“It is possible we will include our sister Company, Crown Baus Capital Corp (CBCA) in this purchase,” noted company CEO Raymond C. Dabney about another opportunity the company has to purchase real estate in Los Angeles.
News and Notes
You're talkin' to that reefer man… Reporting to shareholders is FinCanna Capital Corp. (CSE:CALI), who announced on Monday a review of their business objectives. The company began trading on the CSE in late December, raising CAD$14 million before trading began. Their primary investment is in Cultivation Technologies Inc. which plans to build a new facility in Coachella, California.
Everyday we be burnin' not concernin' what nobody wanna say… Announcing a research and development initiative is NeutriSci International Inc. (TSX-V:NU) who entered into an agreement with Scientus Pharma Inc. this week. Together the companies hope to develop a medical cannabinoid product. They plan to distribute it throughout Canada.
I would not feel so all alone/ Everybody must get stoned… Not completing its annual filings was Namaste Technologies Inc. (CSE:N) who as a result received a cease trade order from the British Columbia Securities Commission.